Supernus Pharmaceuticals Inc — Cash Flow (NASDAQ:SUPN) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 138.4 M127.13 M116.83 M111.08 M171.95 M 71.88 M Cash from investing activities -34.7 M-81.91 M-216.66 M268.73 M-189.87 M 42.78 M Cash from financing activities 3.56 M-130.42 M-10.48 M397.88 M12.19 M 6.49 M Free cash flow 134.95 M127.13 M116.83 M111.08 M171.23 M 70.75 M

Haberler

TD Cowen, Supernus Pharmaceuticals için hisse hedefini yükseltti

TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch

Supernus Pharmaceuticals hissesi 57,76 dolarla zirve yaptı

Supernus Pharmaceuticals stock hits 52-week high at $57.76

Cantor Fitzgerald, Supernus hissesi için Overweight önerisini korudu

Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

Supernus kazancı $0,48 ile beklentilere göre daha kötü, kâr ise beklentilere göre yüksek

Supernus earnings missed by $0.48, revenue topped estimates

Supernus 3. çeyrek kârlılık şokunun ardından kazanç testinde

Supernus faces earnings test after Q3 shock to profitability

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline